

Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapy

Submission date

12/09/2006

Recruitment status

No longer recruiting

Registration date

25/01/2008

Overall study status

Completed

Last Edited

17/02/2015

Condition category

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☒ Results

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Patrick Bell

Contact details

East Wing

Royal Victoria Hospital

Grosvenor Road

Belfast

United Kingdom

BT12 6BA

+44 (0)289 063 3423

patrick.bell@royalhospitals.n-i.nhs.uk

Additional identifiers

Protocol serial number

RGHT000278

Study information

Scientific Title

Studies of insulin action in patients at increased vascular risk: modulation by anti-hypertensive and endocrine replacement therapy

Study objectives

Insulin resistance is present in common clinical conditions including diabetes and hypertension, and in less common ones such as hypopituitarism. Each of these is associated with vascular risk and increasing evidence suggests that insulin resistance may contribute. The studies described aim to define better how treatment interventions in these conditions affect insulin sensitivity.

Studies in the Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, using detailed assessment of insulin action in carefully controlled protocols have influenced the debate about the most appropriate anti-hypertensive treatment. Our most recent data suggest that combining thiazide diuretics even at low doses with an angiotensin converting enzyme (ACE) inhibitor will increase insulin resistance in hypertensive type two diabetic patients. We plan a similar comparison in nondiabetic hypertensive patients in whom this efficacious combination may be without this adverse effect. We will also compare low dose thiazide/ACE inhibitor with calcium channel blocker/ACE inhibitor, a key choice in current guidelines.

We have previously investigated the impact of hydrocortisone and growth hormone on insulin action in hypopituitarism. Levels of dehydroepiandrosterone (DHEA), an adrenal steroid hormone, are reduced in hypopituitarism. DHEA is available in the United States of America (USA) as replacement therapy and has been shown to improve quality of life in patients with hypoadrenalism. Its effect on insulin sensitivity is controversial and has not been widely researched in patients with hypopituitarism. Using a placebo controlled cross-over trial, we plan to study DHEA replacement in hypopituitarism.

The results of the studies described will influence future therapeutic approaches in these at risk patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Office for Research Ethics Committee in Northern Ireland (ORECNI), 29/08/2006, ref: 06/NIR03/93

Study design

Randomised double-blind placebo-controlled cross-over study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypertension, type 2 diabetes, hypopituitarism

Interventions

Protocols one and two:

Medications will be withdrawn and replaced with placebo for a six week run in. Patients will be

randomised to captopril plus study drug (bendroflumethiazide) or captopril plus placebo in protocol one and captopril plus bendroflumethiazide or plus amlodipine in protocol two for 12 weeks. There will be a six week washout, then cross over to the alternative study arm.

Protocol three:

Hydrocortisone therapy will be standardised for four weeks. Patients will receive either dehydroepiandrosterone or placebo for 12 weeks. As for previous protocols, there will be a six week wash out then cross over to the other treatment arm. Insulin action will be assessed after placebo run in and each 12 weeks study period using the hyperinsulinaemic euglycaemic clamp method.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Captopril, bendroflumethiazide, amlodipine

Primary outcome(s)

Insulin resistance

Key secondary outcome(s))

Quality of life following dehydroepiandrosterone replacement

Completion date

01/08/2008

Eligibility

Key inclusion criteria

1. Under 65 years old
2. Protocol one: essential hypertension, mild or newly diagnosed
3. Protocol two: type two diabetes and hypertension
4. Protocol 3: hypopituitarism, female, low basal DHEA levels

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Secondary hypertension
2. Obesity
3. Cardiac, renal or hepatic disease
4. History of gout
5. Those in receipt of any additional medications that may affect insulin action
6. Type two diabetics with dipstick positive proteinuria

Date of first enrolment

19/09/2006

Date of final enrolment

01/08/2008

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Royal Victoria Hospital

Belfast

United Kingdom

BT12 6BA

Sponsor information

Organisation

Royal Group Hospitals Trust (UK)

ROR

<https://ror.org/03rq50d77>

Funder(s)

Funder type

Government

Funder Name

Research and Development Office (UK) - Department of Health and Social Security

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2012		Yes	No
Results article	results	01/04/2013		Yes	No